ST Segment Elevation Myocardial Infarction Clinical Trial
Official title:
Intracoronary Infusion of Alprostadil and Nitroglycerin With Targeted Perfusion Microcatheter in STEMI Patients With Coronary Slow Flow Phenomenon
The study intends to evaluate the efficacy of different medicine delivering by targeted perfusion catheter in coronary administration on coronary blood flow in STEMI patients with CSFP.
The goal of STEMI therapy is to successfully restore epicardial blood flow. PCI has been
documented as being the most effective method for restoration of epicardial blood flow.
However, stenting does not necessarily equate to epicardial blood flow; not every patient
achieves TIMI 3 flow after successful PCI.
Currently, there are two main types of interventions to improve epicardial blood flow. One is
the mechanical method, which included thrombus aspiration catheter and the distal protective
devices. It has been confirmed that the mechanical method can effectively improve epicardial
and myocardial perfusion in patient with part of large vessels and high burden thrombus. But
for patients with small vessels and no obvious visual thrombus, the efficacy is not
significant.
The other intervention is medicine which included GP IIb/IIIa receptor antagonist, adenosine,
sodium nitroprusside, verapamil etc. Part of the drugs have some effect but the overall
clinical efficacy is still not satisfied.
The study intends to use targeted perfusion catheter to deliver drug to the distal targeted
blood vessels. TFG and cTFC are applied to evaluate the efficacy of treatment with
Alprostadil or Nitroglycerin on coronary blood flow in STEMI patients with CSFP.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02869906 -
Instantaneous Wave-Free Ratio and Fractional Flow Reserve for the Assessment of Non Culprit Lesions in Patients With ST-segment Elevation Myocardial Infarction
|
N/A | |
| Not yet recruiting |
NCT03895983 -
ST Segment Resolution After Primary Percutaneous Coronary Intervention.
|
||
| Not yet recruiting |
NCT03252665 -
Efficacy of Intracoronary Infusion of Different Medicine in STEMI Patients Undergoing Primary PCI
|
Phase 4 | |
| Completed |
NCT02026219 -
Comparison of Clopidogrel and Ticagrelor on Microvascular Dysfunction in ST-Segment Elevation Myocardial Infarction
|
Phase 4 | |
| Completed |
NCT03247738 -
Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI
|
Phase 4 | |
| Recruiting |
NCT05461781 -
Distal Transradial Access for Primary PCI in STEMI Patients to Prevent RAO
|
N/A | |
| Recruiting |
NCT03561389 -
iFR-guided Revascularization in STEMI
|
||
| Completed |
NCT01538303 -
Microvascular Dysfunction in Acute Myocardial Infarction (AMI) and Its Relation to Outcome
|
||
| Recruiting |
NCT02979236 -
Italian Multi-center Registry of Self-apposing Coronary Stent in Patients With STEMI
|
N/A | |
| Completed |
NCT05705089 -
Rivaroxaban vErsus Warfarin for Antithrombotic TheRapy in Patients With LeFt Ventricular Thrombus After Acute STEMI
|
Phase 3 | |
| Completed |
NCT01897350 -
Myocardial Oedema in ST Segment Elevation Myocardial Infarction Myocardial
|
N/A | |
| Not yet recruiting |
NCT03753269 -
Early Intracoronary Administration of Fasudil in the Primary PCI of ST-segment-Elevation Myocardial Infarction
|
Phase 4 | |
| Completed |
NCT03234348 -
MAGnesium-based Bioresorbable Scaffold in ST Segment Elevation Myocardial Infarction
|
Phase 3 | |
| Recruiting |
NCT03406832 -
Prevention of Coronary Slow Flow or No-Reflow During EPCI in Patients With Acute STEMI
|
N/A | |
| Recruiting |
NCT03406819 -
Prevention of Coronary Slow Flow or No-Reflow During PPCI in Patients With Acute STEMI
|
N/A | |
| Recruiting |
NCT03508232 -
Doxycycline to Protect Heart Muscle After Heart Attacks
|
Phase 2 | |
| Recruiting |
NCT04220736 -
Early Prediction of QFR in STEMI-Pharmaco-invasice
|
||
| Completed |
NCT03780335 -
Early Prediction of QFR in STEMI-I
|
||
| Recruiting |
NCT03787745 -
Ischemic Postconditioning in STEMI Patients Treated With Primary PCI
|
N/A | |
| Recruiting |
NCT03621111 -
A Trial on the Role of Community Pharmacist in Improving Adherence and Clinical Outcomes in Post-Infarction
|
N/A |